Featured
Impact of Glycemic Control and Hypoglycemia on Diabetic Retinopathy
Both diabetes and diabetes medications can affect the retina.
By Deborah Li, BA, Andre Galenchik-Chan, BS, Diane Chernoff, BA , et al.
The Landscape of Gene Therapy for Diabetic Retinopathy
Two major clinical trials are under way.
By Priya Vakharia, MD, David A. Eichenbaum, MD
The Evolution of Clinical Trial Endpoints for Diabetic Retinopathy
New scales are being developed that could enhance insights available from trials.
By David R. Lally, MD, Jay S. Pepose, MD, PhD, George N. Magrath, MD, MBA, MS, et al.
Web Exclusives
The Continuing Evolution of Diabetic Retinal Disease Staging
New initiatives could usher in a new era of disease evaluation.
By Daniel F. Kiernan, MD, FACS
Supported Content
Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
The long-term goal of eradicating GA or halting disease progression finally has a beacon of hope.
By Daniel K. Bennett, MD
Departments
Upfront: New Efforts to Halt Diabetic Eye Disease
"Diabesity" is being called the biggest epidemic in human history.
By Peter K. Kaiser, MD
Retina Cases: Vision Loss in Combined Hamartoma of the Retina and Retinal Pigment Epithelium
Vitrectomy and membrane peeling surgery can be useful in these cases.
By Elham Sadeghi, MD , Andrew W. Eller, MD , Jay Chhablani, MD
Uveitis Corner: Syphilitic Uveitis Update
As cases rise, ophthalmologists should consider syphilis among differential diagnoses.
By David M. Hinkle, MD, Emily Laurent, MD
Coding: Medicare Considerations of Compounded Drugs
Billing differs for FDA-approved and compounded drugs.
By Brandy H. Sperry, COMT, COE, CPC, CPMA
Clinical Trial Update June 2024
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
New data could support its use.
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
News
First Patient Dosed in Retinitis Pigmentosa Intravitreal Treatment Trial
The gene therapy company ViGeneron announced that the first patient has been dosed in its phase 1b clinical trial evaluating VG901 to treat retinitis pigmentosa.
By Rochelle Nataloni, contributing writer
FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder
Approval was based on positive results from the CHAMPION-NMOSD phase 3 trial.
By Rochelle Nataloni, contributing writer
Regenxbio Publishes Data Supporting One-time Use of Gene Therapy for Wet AMD
Two-year data were published in The Lancet.
By Rochelle Nataloni, contributing writer
Ocular Therapeutix Reports Positive Top-line Phase 1 Data for Axpaxli
Overall, Axpaxli demonstrated promising safety and efficacy outcomes.
By Rochelle Nataloni, contributing writer
Regeneron Responds to Complaint of Fraudulent Drug Price Reporting
The United States filed a complaint under the False Claims Act.
By Rochelle Nataloni, contributing writer
Ocugen Announces Milestones in OCU410 and OCU400 Clinical Trials
The company announced positive results from cohort 1 of the phase 1/2 ArMaDa clinical trial.
By Rochelle Nataloni, contributing writer
Post Hoc Analysis of Phase 2/3 PHOTON Trial Outcomes Presented at ARVO
Researchers investigated the effects of aflibercept 8 mg on patients with DME, focusing on BCVA.
By Rochelle Nataloni, contributing writer
ARCHER Trial Data Indicate ANX007 Protects Against GA Vision Loss
New analysis of data was reported from the phase 2 ARCHER trial.
By Jim Gallagher, managing editor
DME Treatment AG-73305 Found Safe, Effective in Phase 2b Trial
A single intravitreal dose showed improvement lasting up to 24 weeks.
By Jim Gallagher, managing editor
FDA Approves First Biosimilars to Eylea
Both Yesafili and Opuviz are approved as interchangeable biosimilars to aflibercept.
By Jim Gallagher, managing editor
Portable Device Cleared for DR Screening and Diagnosis
AEYE Aurora is the first handheld device approved by the FDA for diagnosis of diabetic retinopathy.
Harrow Provides Triesence Relaunch Update
Production of the preservative-free corticosteroid could resume later in 2024.